DekaBank Deutsche Girozentrale lowered its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR – Free Report) by 84.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,875 shares of the medical instruments supplier’s stock after selling 25,878 shares during the period. DekaBank Deutsche Girozentrale’s holdings in OraSure Technologies were worth $40,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in OraSure Technologies by 1.2% during the third quarter. Vanguard Group Inc. now owns 5,396,285 shares of the medical instruments supplier’s stock worth $32,000,000 after buying an additional 64,367 shares in the last quarter. Earnest Partners LLC raised its position in OraSure Technologies by 5.2% during the first quarter. Earnest Partners LLC now owns 5,123,334 shares of the medical instruments supplier’s stock worth $34,736,000 after acquiring an additional 251,955 shares during the last quarter. State Street Corp raised its position in OraSure Technologies by 1.9% during the second quarter. State Street Corp now owns 3,440,307 shares of the medical instruments supplier’s stock worth $9,323,000 after acquiring an additional 63,392 shares during the last quarter. Dimensional Fund Advisors LP raised its position in OraSure Technologies by 6.9% during the first quarter. Dimensional Fund Advisors LP now owns 3,156,930 shares of the medical instruments supplier’s stock worth $21,405,000 after acquiring an additional 205,126 shares during the last quarter. Finally, Neuberger Berman Group LLC raised its position in OraSure Technologies by 8.7% during the third quarter. Neuberger Berman Group LLC now owns 2,953,375 shares of the medical instruments supplier’s stock worth $11,214,000 after acquiring an additional 236,827 shares during the last quarter. Hedge funds and other institutional investors own 93.50% of the company’s stock.
OraSure Technologies Trading Up 0.6 %
Shares of OSUR opened at $5.25 on Thursday. The company has a 50-day moving average of $6.56 and a two-hundred day moving average of $6.82. The stock has a market cap of $401.68 million, a P/E ratio of 7.29 and a beta of 0.15. OraSure Technologies, Inc. has a 12-month low of $4.38 and a 12-month high of $8.45.
Analyst Ratings Changes
Separately, Evercore ISI cut their target price on shares of OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating for the company in a research report on Thursday, April 4th. Three investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $6.38.
Check Out Our Latest Research Report on OraSure Technologies
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Further Reading
- Five stocks we like better than OraSure Technologies
- The How And Why of Investing in Oil Stocks
- United Airlines Soars on Earnings Beat
- How to Choose Top Rated Stocks
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.